Cubist will boost antibiotics lineup with Optimer and Trius buys

07/31/2013 | Reuters · Bloomberg Businessweek

Cubist Pharmaceuticals has deals to acquire antibiotics-makers Optimer Pharmaceuticals for about $801 million and Trius Therapeutics for $818 million contingent on certain milestones in a bid to increase its product pipeline. The deal grants Cubist access to Optimer's recently approved drug Dificid for Clostridium difficile-associated diarrhea and Trius' late-stage antibiotic tedizolid phosphate.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL